Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation - Takeaways - MDSpire

Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation

  • By

  • Lilli Leimi

  • Kirsi Jahnukainen

  • Helena Olkinuora

  • Seppo Meri

  • Kim Vettenranta

  • February 17, 2022

  • 0 min

Share

  • 1

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is effective for various hematologic and metabolic disorders in pediatric patients.

  • 2

    Despite improved overall survival, treatment-related mortality (TRM) and vascular complications like CLS, TMA, and VOD remain significant challenges.

  • 3

    Vascular complications post-transplant are variable, complicating early detection and timely intervention, which are critical for patient outcomes.

  • 4

    This study analyzed 218 pediatric allo-HSCT patients to assess the incidence and clinical variation of acute vascular toxicity within 100 days post-transplant.

  • 5

    Key vascular complications were documented, with specific attention to endothelial dysfunction, highlighting the need for improved monitoring and management.

Original Source(s)

Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation

  • by Lilli Leimi, Kirsi Jahnukainen, Helena Olkinuora, Seppo Meri, Kim Vettenranta

  • February 17, 2022

Related Content

Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review

Computed tomography-derived sarcopenia, enteral nutritional support, and febrile neutropenia burden in children with acute lymphoblastic leukemia: a retrospective cohort study

Context-dependent functions of ALKBH5: a mechanistic framework linking cellular stress responses, immune regulation, viral infection, and therapeutic vulnerabilities